Show simple item record

dc.contributor.authorMarkus, Havell
dc.contributor.authorChandrananda, Dineika
dc.contributor.authorMoore, Elizabeth
dc.contributor.authorMouliere, Florent
dc.contributor.authorMorris, James
dc.contributor.authorBrenton, James D
dc.contributor.authorSmith, Christopher G
dc.contributor.authorRosenfeld, Nitzan
dc.date.accessioned2022-02-04T16:16:33Z
dc.date.available2022-02-04T16:16:33Z
dc.date.issued2022-12
dc.date.submitted2021-09-28
dc.identifier.others41598-022-05606-z
dc.identifier.other5606
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/333650
dc.description.abstract<jats:title>Abstract</jats:title><jats:p>Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent studies have been focused on understanding the non-random fragmentation pattern of cfDNA. These studies have investigated fragment sizes, genomic position of fragment end points, and fragment end motifs. Although these features have been described and shown to be aberrant in cancer patients, there is a lack of understanding of how the individual and integrated analysis of these features enrich ctDNA fraction and enhance ctDNA detection. Using whole genome sequencing and copy number analysis of plasma samples from 5 high grade serious ovarian cancer patients, we observed that (1) ctDNA is enriched not only in fragments shorter than mono-nucleosomes (~ 167 bp), but also in those shorter than di-nucleosomes (~ 240–330 bp) (28–159% enrichment). (2) fragments that start and end at the border or within the nucleosome core are enriched in ctDNA (5–46% enrichment). (3) certain DNA motifs conserved in regions 10 bp up- and down- stream of fragment ends (i.e. cleavage sites) could be used to detect tumor-derived fragments (10–44% enrichment). We further show that the integrated analysis of these three features resulted in a higher enrichment of ctDNA when compared to using fragment size alone (additional 7–25% enrichment after fragment size selection). We believe these genome wide features, which are independent of genetic mutational changes, could allow new ways to analyze and interpret cfDNA data, as significant aberrations of these features from a healthy state could improve its utility as a diagnostic biomarker.</jats:p>
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectArticle
dc.subject/631/67
dc.subject/631/114/2785
dc.subject/692/53/2421
dc.subjectarticle
dc.titleRefined characterization of circulating tumor DNA through biological feature integration
dc.typeArticle
dc.date.updated2022-02-04T16:16:33Z
prism.issueIdentifier1
prism.publicationNameScientific Reports
prism.volume12
dc.identifier.doi10.17863/CAM.81068
dcterms.dateAccepted2022-01-07
rioxxterms.versionofrecord10.1038/s41598-022-05606-z
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidBrenton, James [0000-0002-5738-6683]
dc.identifier.eissn2045-2322
pubs.funder-project-idCRUK Cambridge Institute (A29580)
pubs.funder-project-idEuropean Research Council (337905)
cam.issuedOnline2022-02-04


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record